Developing inhibitors or agonists for key molecules such as NLRP3 inflammasome, ALKBH5, MTHFD2, or specific immunoproteasome subunits could lead to novel immune-based strategies for atherosclerosis, offering more precise and effective clinical treatments. Here, MTHFD2 is linked to atherosclerosis.